For the quarter ending March 31, 2025, the Company expects revenue growth of 22% to 25%. Revenue growth ranges by product line are: Total Omnipod of 23% to 26%; U.S. Omnipod of 21% to 24%; International Omnipod of 28% to 31%; Drug Delivery of (10)% to (5)%
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- PODD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Biote announcesTerry Weber retires Bret Christensen named CEO
- 3 Best Growth Stocks to Buy Now, 1/31/2025, According to Analysts
- Insulet launches Omnipod 5 in five more countries in Europe
- Insulet price target raised to $315 from $305 at Bernstein